Skip to main content

Ingenuity Extends Pathway Analysis Software Deal With Merck

NEW YORK (GenomeWeb News) — Ingenuity Systems today said it has extended a licensing agreement with Merck that allows the drug maker to continue using its Ingenuity Pathways Analysis Software.
 
Under the terms of the “multi-year” agreement, Merck will continue to use the IPA software for research in “multiple therapeutic areas,” Ingenuity said.
 
The original agreement was signed in 2004, but the company did not say when the extended licensing contract will expire.
 
Ingenuity said the software supports biomarker target identification and validation, predictive toxicology, and pharmacogenomics on “all high throughput analysis platforms.”
 
Financial terms of the agreement were not released.

Filed under

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.